ConductScience.org, home

Paper26164151

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.

Garner F and 4 others. Anticancer Drugs, 2015. Cited by 132 papers, by iCite.

Cite this record

ConductScience Library. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Papers, record 26164151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26164151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
PubMed
Journal
Anticancer Drugs
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
132
iCite
Relative citation ratio, by iCite
3.7
iCite
Revised in PubMed
2018-11-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Garner FFiona
2Shomali MMaysoun
3Paquin DDotty
4Lyttle CRC Richard
5Hattersley GGary

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Brain NeoplasmsMajor topic
Breast NeoplasmsMajor topic
Estrogen Receptor alphaMajor topic
Phenylurea CompoundsMajor topic
ortho-AminobenzoatesMajor topic
Administration, Oral
Animals
Binding, Competitive
Bone Density
Cell Proliferation
Female
Heterografts
MCF-7 Cells
Mice, Nude
Neoplasm Transplantation
Osteoporosis
Ovariectomy
Rats, Sprague-Dawley
Uterus

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116092128Steroid hormone receptor signaling in tumorigenesis.J Cell Biochem2005https://conductscience.org/library/papers/16092128PubMed
21773131The ovariectomized rat model of postmenopausal bone loss.Bone Miner1991https://conductscience.org/library/papers/1773131PubMed
316515478Estrogen receptors as therapeutic targets in breast cancer.Curr Top Med Chem2006https://conductscience.org/library/papers/16515478PubMed
417186017Chemoprevention of breast cancer with selective oestrogen-receptor modulators.Nat Rev Cancer2007https://conductscience.org/library/papers/17186017PubMed
517259555Estrogen-related receptor alpha as a therapeutic target in cancer.Endocr Relat Cancer2006https://conductscience.org/library/papers/17259555PubMed
617440819SERMs for the treatment and prevention of breast cancer.Rev Endocr Metab Disord2007https://conductscience.org/library/papers/17440819PubMed
717993238Estrogen receptors in resistance to hormone therapy.Adv Exp Med Biol2007https://conductscience.org/library/papers/17993238PubMed
820855825Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.J Clin Oncol2010https://conductscience.org/library/papers/20855825PubMed
921501600The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.Biochem Pharmacol2011https://conductscience.org/library/papers/21501600PubMed
1021761331Estrogen and progesterone in normal mammary gland development and in cancer.Horm Cancer2011https://conductscience.org/library/papers/21761331PubMed
1122648069Estrogen receptors and human disease: an update.Arch Toxicol2012https://conductscience.org/library/papers/22648069PubMed
1223178278Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.Steroids2013https://conductscience.org/library/papers/23178278PubMed
1323062036The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.Curr Clin Pharmacol2013https://conductscience.org/library/papers/23062036PubMed
1424373794Use of SERMs for treatment in postmenopausal women.J Steroid Biochem Mol Biol2014https://conductscience.org/library/papers/24373794PubMed
1525380844Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.Cancer Discov2015https://conductscience.org/library/papers/25380844PubMed
1625879485Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.J Med Chem2015https://conductscience.org/library/papers/25879485PubMed
1712040178Connections and regulation of the human estrogen receptor.Science2002https://conductscience.org/library/papers/12040178PubMed
1815202583Hormone- and chemotherapy-induced bone loss in breast cancer.Oncology (Williston Park)2004https://conductscience.org/library/papers/15202583PubMed
193283939The steroid and thyroid hormone receptor superfamily.Science1988https://conductscience.org/library/papers/3283939PubMed
2016421368Estrogen carcinogenesis in breast cancer.N Engl J Med2006https://conductscience.org/library/papers/16421368PubMed

Download CSV of references

Cited by77

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.

PMIDTitleJournalYearIn PapersSource
42642633Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells.Nat Cancer2026https://conductscience.org/library/papers/42642633PubMed
42510955Targeting Estrogen Receptor for Breast Cancer.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42510955PubMed
42449589A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.Cancers (Basel)2026https://conductscience.org/library/papers/42449589PubMed
42100504Deciphering inter-organ communication: The multi-organ-bone axis in osteoporosis and emerging therapeutic strategies.J Orthop Translat2026https://conductscience.org/library/papers/42100504PubMed
41474498Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions.Discov Oncol2025https://conductscience.org/library/papers/41474498PubMed
41430072Biological and computer-aided evaluation of 3-methoxy-13α-estrone-16α-diphenylphosphine oxide as a new antiestrogenic agent.Sci Rep2025https://conductscience.org/library/papers/41430072PubMed
41383111The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.Mol Cancer Ther2026https://conductscience.org/library/papers/41383111PubMed
41108678Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment.Cancer2025https://conductscience.org/library/papers/41108678PubMed
40172823Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery.Mol Divers2025https://conductscience.org/library/papers/40172823PubMed
40163189Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer.Curr Treat Options Oncol2025https://conductscience.org/library/papers/40163189PubMed
39991467Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/39991467PubMed
39891710Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?Endocrinology2025https://conductscience.org/library/papers/39891710PubMed
39821038Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.Adv Exp Med Biol2025https://conductscience.org/library/papers/39821038PubMed
39820652Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.Clin Cancer Res2025https://conductscience.org/library/papers/39820652PubMed
39767607Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer.Biomedicines2024https://conductscience.org/library/papers/39767607PubMed
39652577Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.Cancer Res2025https://conductscience.org/library/papers/39652577PubMed
39585895Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).J Med Chem2024https://conductscience.org/library/papers/39585895PubMed
39179659Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/39179659PubMed
39118705Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review.Ann Med Surg (Lond)2024https://conductscience.org/library/papers/39118705PubMed
39022350Structure-Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators.ACS Pharmacol Transl Sci2024https://conductscience.org/library/papers/39022350PubMed

See all 77 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
ESR22100PubTator's text mininghttps://conductscience.org/library/genes/2100NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26164151

GET https://conductscience.org/api/papers/v1/26164151/cited_by?page=2